Moderna Inc. (MRNA) exhibits 55.3% gross margins and -34.1% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 55.3% gross profitability converts into -60.0% operating margin and -34.1% ROIC, outpacing sector cost of capital.
ROIC: -34.1% // GM: 55.3%YoY revenue trajectory of -39.9% paired with -2.32% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -39.9% // FCF YLD: -2.32%Altman Z-Score of 15.07 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 15.07 // F-SCORE: 5/9Trading at 24.0x trailing P/E (32.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 0.65 put/call ratio around $218.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.65Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -60.0% net margins.
NET MARGIN: -60.0% // D/E: 0.07x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MRNA & activate live FRED threshold breach alerts.